Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J W Rose

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Central Nervous System Trauma : Journal of the American Paralysis Association|January 1, 1987
Improved recovery from a traumatic-hypoxic brain injury in cats by intracisternal injection of an anion transport inhibitorH K Kimelberg, E J Cragoe, L R Nelson, et al.
The Journal of Biological Chemistry|January 15, 1993
Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIaR M Scarborough, M A Naughton, W Teng, et al.
Annals of Neurology|July 1, 1988
Human antiidiotypic antibody against opiate receptorsB F Roy, W D Bowen, J S Frazier, et al.
Biochemistry|September 24, 1996
Binding of a novel 50-kilodalton alboaggregin from Trimeresurus albolabris and related viper venom proteins to the platelet membrane glycoprotein Ib-IX-V complex. Effect on platelet aggregation and glycoprotein Ib-mediated platelet activationR K Andrews, M H Kroll, C M Ward, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1986
Polypeptide specificities of measles virus-reactive T cell lines and clones derived from a patient with multiple sclerosisJ R Richert, J W Rose, C Reuben-Burnside, et al.
Neurology|July 1, 1995
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study GroupK P Johnson, B R Brooks, J A Cohen, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 30, 2000
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study GroupK P Johnson, B R Brooks, C C Ford, et al.
Journal of Medicinal Chemistry|January 22, 1998
Fibrinogen receptor (GPIIb-IIIa) antagonists derived from 5,6-bicyclic templates. Amidinoindoles, amidinoindazoles, and amidinobenzofurans containing the N-alpha-sulfonamide carboxylic acid function as potent platelet aggregation inhibitorsT Su, M A Naughton, M S Smyth, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 11, 2003
Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trialK P Johnson, B R Brooks, C C Ford, et al.
Neurology|March 21, 2002
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995K P Johnson, B R Brooks, J A Cohen, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Central Nervous System Trauma : Journal of the American Paralysis Association|January 1, 1987
Improved recovery from a traumatic-hypoxic brain injury in cats by intracisternal injection of an anion transport inhibitorH K Kimelberg, E J Cragoe, L R Nelson, et al.
The Journal of Biological Chemistry|January 15, 1993
Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIaR M Scarborough, M A Naughton, W Teng, et al.
Annals of Neurology|July 1, 1988
Human antiidiotypic antibody against opiate receptorsB F Roy, W D Bowen, J S Frazier, et al.
Biochemistry|September 24, 1996
Binding of a novel 50-kilodalton alboaggregin from Trimeresurus albolabris and related viper venom proteins to the platelet membrane glycoprotein Ib-IX-V complex. Effect on platelet aggregation and glycoprotein Ib-mediated platelet activationR K Andrews, M H Kroll, C M Ward, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1986
Polypeptide specificities of measles virus-reactive T cell lines and clones derived from a patient with multiple sclerosisJ R Richert, J W Rose, C Reuben-Burnside, et al.
Neurology|July 1, 1995
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study GroupK P Johnson, B R Brooks, J A Cohen, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 30, 2000
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study GroupK P Johnson, B R Brooks, C C Ford, et al.
Journal of Medicinal Chemistry|January 22, 1998
Fibrinogen receptor (GPIIb-IIIa) antagonists derived from 5,6-bicyclic templates. Amidinoindoles, amidinoindazoles, and amidinobenzofurans containing the N-alpha-sulfonamide carboxylic acid function as potent platelet aggregation inhibitorsT Su, M A Naughton, M S Smyth, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 11, 2003
Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trialK P Johnson, B R Brooks, C C Ford, et al.
Neurology|March 21, 2002
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995K P Johnson, B R Brooks, J A Cohen, et al.
Pageof 6